Enzymatic kinase assays and docking simulation studies have shown that the natural product wrightiadione displays inhibitory activity toward TrkA and PLK3. In this study, the template of wrightiadione served as a starting point for Trk inhibitor development campaigns. Molecular simulation provided structural insights for the design of derivatives that were efficiently generated by our recently developed 3-step tandem synthetic approach, resulting in the discovery of compound 2h with biochemical potency at the single-digit micromolar level. © 2015 Elsevier Ltd. All rights reserved1111sciescopu
International audienceAn efficient synthetic strategy was developed to modulate the structure of the...
Protein kinase D (PKD) has emerged as a potential therapeutic target in multiple pathological condit...
We have identified several series of small molecule inhibitors of TrkA with unique binding modes. Th...
Tropomyosin-related kinase A (TrkA) is a promising target for the development of cancer and pain the...
Tropomyosin-related kinase A (TrkA) is considered a promising target in the development of a therape...
Kinase inhibitors have been one of the most widely studied drug classes over the last 30 years. Due ...
Protein kinases act as key mediators of essential biochemical pathways through the phosphorylation o...
The solvent-front (SF), gatekeeper, and xDFG motif mutations of tropomyosin receptor kinase (TRK) me...
Tropomyosin receptor kinase (TRK) represents an attractive oncology target for cancer therapy relate...
Despite the impressive accomplishments in the development of small molecule kinase inhibitors over t...
Protein kinase D (PKD) has emerged as a potential therapeutic target in multiple pathological condit...
In recent years, DAPK-related apoptosis-inducing protein kinase 2 (DRAK2) has emerged as a promising...
Hormones of the neurotrophin family, nerve growth factor (NGF), brain derived neurotrophic factor (B...
Although stem cell factor receptor (c-KIT) kinase is responsible for various malignant human cancers...
DRAK2 emerged as a promising drug target for the treatment of autoimmune diseases and to prevent gra...
International audienceAn efficient synthetic strategy was developed to modulate the structure of the...
Protein kinase D (PKD) has emerged as a potential therapeutic target in multiple pathological condit...
We have identified several series of small molecule inhibitors of TrkA with unique binding modes. Th...
Tropomyosin-related kinase A (TrkA) is a promising target for the development of cancer and pain the...
Tropomyosin-related kinase A (TrkA) is considered a promising target in the development of a therape...
Kinase inhibitors have been one of the most widely studied drug classes over the last 30 years. Due ...
Protein kinases act as key mediators of essential biochemical pathways through the phosphorylation o...
The solvent-front (SF), gatekeeper, and xDFG motif mutations of tropomyosin receptor kinase (TRK) me...
Tropomyosin receptor kinase (TRK) represents an attractive oncology target for cancer therapy relate...
Despite the impressive accomplishments in the development of small molecule kinase inhibitors over t...
Protein kinase D (PKD) has emerged as a potential therapeutic target in multiple pathological condit...
In recent years, DAPK-related apoptosis-inducing protein kinase 2 (DRAK2) has emerged as a promising...
Hormones of the neurotrophin family, nerve growth factor (NGF), brain derived neurotrophic factor (B...
Although stem cell factor receptor (c-KIT) kinase is responsible for various malignant human cancers...
DRAK2 emerged as a promising drug target for the treatment of autoimmune diseases and to prevent gra...
International audienceAn efficient synthetic strategy was developed to modulate the structure of the...
Protein kinase D (PKD) has emerged as a potential therapeutic target in multiple pathological condit...
We have identified several series of small molecule inhibitors of TrkA with unique binding modes. Th...